Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Toward the next generation EGFR inhibitors: an overview of osimertinib resistance mediated by EGFR mutations in non-small cell lung cancer
Yufeng Li, Tianyu Mao, Jing Wang, et al.
Cell Communication and Signaling (2023) Vol. 21, Iss. 1
Open Access | Times Cited: 36

Showing 1-25 of 36 citing articles:

Unveiling the potential effects of resveratrol in lung cancer treatment: Mechanisms and nanoparticle-based drug delivery strategies
Behnam Najafiyan, Zahra Bokaii Hosseini, Samar Esmaelian, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 172, pp. 116207-116207
Open Access | Times Cited: 18
Targeting HER3 to overcome EGFR TKI resistance in NSCLC
Qiuqiang Chen, Gang Jia, Xilin Zhang, et al.
Frontiers in Immunology (2024) Vol. 14
Open Access | Times Cited: 8
Overcoming tyrosine kinase inhibitor resistance in lung cancer brain metastasis with CTLA4 blockade
Minjie Fu, Jiaxu Zhao, Licheng Zhang, et al.
Cancer Cell (2024) Vol. 42, Iss. 11, pp. 1882-1897.e7
Closed Access | Times Cited: 7
The Resistance to EGFR-TKIs in Non-Small Cell Lung Cancer: From Molecular Mechanisms to Clinical Application of New Therapeutic Strategies
Carmelo Laface, Felicia Maria Maselli, Anna Santoro, et al.
Pharmaceutics (2023) Vol. 15, Iss. 6, pp. 1604-1604
Open Access | Times Cited: 19
Unraveling the secrets: Evolution of resistance mediated by membrane proteins
Xue Yang, Min Li, Zi-Chang Jia, et al.
Drug Resistance Updates (2024) Vol. 77, pp. 101140-101140
Open Access | Times Cited: 6
Epsin3 promotes non-small cell lung cancer progression via modulating EGFR stability
Huiling Su, Jie Shen, Chenzi Gao, et al.
Cell & Bioscience (2025) Vol. 15, Iss. 1
Open Access
Possibilities of Overcoming Resistance to Osimertinib in NSCLC Patients with Mutations in the EGFR Gene
Marcin Nicoś, Anna Sroka‐Bartnicka, Ewa Kalinka‐Warzocha, et al.
Cancers (2025) Vol. 17, Iss. 4, pp. 563-563
Open Access
Targeting the Tumor Microenvironment in EGFR-Mutant Lung Cancer: Opportunities and Challenges
Jeong Uk Lim, Junyang Jung, Yeon Wook Kim, et al.
Biomedicines (2025) Vol. 13, Iss. 2, pp. 470-470
Open Access
Amivantamab plus lazertinib vs osimertinib in first-line egfr-mutant advanced non-small cell lung cancer
Md Nazmul Hasan, Misako Nagasaka
Expert Review of Respiratory Medicine (2025)
Closed Access
The coevolutionary landscape of drug resistance in epidermal growth factor receptor: A cancer perspective
Gyan Prakash, Asheesh Shanker
Computers in Biology and Medicine (2025) Vol. 189, pp. 110001-110001
Closed Access
Icotinib in a lung adenocarcinoma patient with acquired EGFR 19del/C797S mutation-mediated resistance to osimertinib: a case report
Fei Cai, Yuanyuan Zhao, Shuxi Song, et al.
Anti-Cancer Drugs (2024)
Closed Access | Times Cited: 3
ALDOA coordinates PDE3A through the β-catenin/ID3 axis to stimulate cancer metastasis and M2 polarization in lung cancer with EGFR mutations
Chia-Ying Yeh, Huei Yu Cai, Han-His Kuo, et al.
Biochemical and Biophysical Research Communications (2024) Vol. 696, pp. 149489-149489
Closed Access | Times Cited: 2
CYP450 and drug efflux transporters polymorphism influence clinical outcomes of Thai osimertinib-treated non-small cell lung cancer patients
Teerapat Majam, Chonlaphat Sukasem, Thanyanan Reungwetwattana, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 5
Rational design and synthesis of 2,4‐dichloro‐6‐methyl pyrimidine derivatives as potential selective EGFRT790M/L858R inhibitors for the treatment of non‐small cell lung cancer
Lei Duan, Cilong Chu, Xiaoling Huang, et al.
Archiv der Pharmazie (2024) Vol. 357, Iss. 5
Closed Access | Times Cited: 1
Monolayer culture alters EGFR inhibitor response through abrogation of microRNA-mediated feedback regulation
Angela Florio, Sarah H. Johnson, Rebecca Salvatori, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 1
A graphSAGE discovers synergistic combinations of Gefitinib, paclitaxel, and Icotinib for Lung adenocarcinoma management by targeting human genes and proteins: the RAIN protocol
Sogand Sadeghi, Ali A. Kiaei, Mahnaz Boush, et al.
medRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 1
Exploring the structural activity relationship of the Osimertinib: A covalent inhibitor of double mutant EGFRL858R/T790M tyrosine kinase for the treatment of Non-Small Cell Lung Cancer (NSCLC)
Bhatu Patil, Kunal V. Bhadane, Iqrar Ahmad, et al.
Bioorganic & Medicinal Chemistry (2024) Vol. 109, pp. 117796-117796
Closed Access | Times Cited: 1
Harnessing Pyroptosis for Lung Cancer Therapy: The Impact of NLRP3 Inflammasome Activation
Rajiv Dahiya, Vijaykumar Sutariya, Sheeba Varghese Gupta, et al.
Pathology - Research and Practice (2024) Vol. 260, pp. 155444-155444
Closed Access | Times Cited: 1
Taxus chinensis var. mairei (Lemée et Lévl) Cheng et L.K. Fu overcomes the resistance to osimertinib in EGFR-mutant non-small-cell lung cancer via suppression of ERK1/2-related cholesterol biosynthesis
Shuying Dai, Gao-chen-xi Zhang, Yuying Xiang, et al.
Journal of Ethnopharmacology (2024) Vol. 334, pp. 118586-118586
Open Access | Times Cited: 1
BLU-945, a potent and selective next-generation EGFR TKI, has antitumor activity in models of osimertinib-resistant non-small-cell lung cancer
Sun Min Lim, Stefanie Schalm, Eun Ji Lee, et al.
Therapeutic Advances in Medical Oncology (2024) Vol. 16
Open Access | Times Cited: 1
Catalytic Lysine745 Targeting Strategy in Fourth-Generation EGFR Tyrosine Kinase Inhibitors to Address C797S Mutation Resistance
Bhatu Patil, Harun Patel
European Journal of Medicinal Chemistry (2024) Vol. 283, pp. 117140-117140
Closed Access | Times Cited: 1
Anti-cancer effects of Bis-oxidized thiopyran derivatives in non-small cell lung cancer: Rational design, synthesis, and activity evaluation
Han Zhang, Cilong Chu, Long Li, et al.
New Journal of Chemistry (2024) Vol. 48, Iss. 6, pp. 2825-2841
Closed Access
Molecular Docking Analysis of Hydroxy Chalcones and Flavones from Anisaldehyde and Veratraldehyde as EGFR Inhibitors: Predicting Anticancer Potential
Wisnu Pambudi, Winarto Haryadi, Sabirin Matsjeh, et al.
Molekul (2024) Vol. 19, Iss. 1, pp. 76-76
Open Access
Traditional and novel genes associated with skin fragility syndrome
Daniela Andrei
(2024)
Open Access
First-line Osimertinib for Lung Cancer With Uncommon EGFR Exon 19 Mutations and EGFR Compound Mutations
Tia Cheunkarndee, Matthew Z. Guo, Stefanie Houseknecht, et al.
JTO Clinical and Research Reports (2024) Vol. 5, Iss. 6, pp. 100686-100686
Open Access
Page 1 - Next Page

Scroll to top